Medicilon Appoints Dr. Wenjie Li as Vice President of the CMC Unit to Expand our CRDMO Business

Medicilon, a one-stop pharmaceutical preclinical research and development CRO, can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times. Over the past 20 years, Medicilon has been involved in the development of 421 new drug and generic drug projects that have obtained IND approvals to initiate clinical trials.

In recent years, based on the "API + formulation" one-stop CMC service platform, Medicilon has expanded from process R&D to industrial commercial production and committed to expanding from preclinical CRO to CRDMO, further strengthening our ability to collaborate with industry partners in the development of new drugs.

Effective March  4 , 2024, Medicilon announced the appointment of Dr. Wenjie Li as Vice President of the CMC Unit. With this appointment, Dr. Wenjie Li will continue to expand and strengthen Medicilon’s services in the CRDMO field, leading the CMC team to improve our R&D CMC capabilities to provide clients with better services efficiently.

Dr. Wenjie Li, holds a Bachelor's degree from Peking University and Masters and Ph.D. degrees in Organic Chemistry from the University of Pittsburgh. He is selected as Shuangchuang talents in Jiangsu Province, Chengdu City's Real Economy and New Economy Talents, and a pioneer in the Zijinshan talent program in Nanjing.

With nearly three decades in pharmaceutical R&D management, Dr. Wenjie Li has deep expertise in drug development, including CMC services and CRO/CDMO management, accumulating rich experience and profound knowledge. He is familiar with all the various stages of new drug and generic drug process development, manufacturing transfer, process validation, commercial production, and application. He is able to accurately control every aspect of drug R&D processes. Additionally, Dr. Li has outstanding academic achievements, publishing over 20 papers in international journals and receiving nearly 20 invention patents, contributing valuable insights to the industry.

Before joining Medicilon, Dr. Wenjie Li was engaged in innovative drug and generic drug process R&D and CMC management at Merck Research Laboratories (USA), Boehringer Ingelheim Pharmaceuticals, Sichuan Kelun Pharmaceutical Research Institute (China), and TransThera Bioscience Co., receiving multiple corporate awards for his outstanding performance and contributions. He also held key positions at WuXi AppTec's US branch and Kingchem Dalian PharmaScience, acquiring extensive experience and leadership skills. His diverse pharmaceutical background and rich work experience have provided Dr. Li with excellent technical capabilities and profound industry insights.

Dr. Wenjie Li, Vice President of CMC Unit at Medicilon, stated: "I am honored to join Medicilon. I am deeply impressed by Medicilon's strategic vision and ambition, and I admire Medicilon's dedication to empowering new drug discovery and development over the past two decades.

I appreciate Medicilon's trust in me. With my years of experience in drug R&D management, I believe I can inject new vitality into Medicilon's development. I look forward to working together with my team to provide high-quality and efficient services in the CMC field for our clients, further contributing to global drug discovery and development in a more impactful way."

Dr. Chunlin Chen, founder & CEO of Medicilon, said: "We welcome Dr. Wenjie Li to the Medicilon family! Dr. Li brings rich global industry experience. He possesses deep local management practice and an international strategic vision. His addition will bring valuable and diverse experience and opportunities to Medicilon's exploration of CRDMO services, helping achieve Medicilon 's strategic goals."